All Courses
>
Prevention
>
2007
>
Early Epirubicin-Induced Myocardial Dysfunction Revealed by Serial Tissue Doppler Echocardiography: Correlation with Inflammatory and Oxidative Stress Markers
Early Epirubicin-Induced Myocardial Dysfunction Revealed by Serial Tissue Doppler Echocardiography: Correlation with Inflammatory and Oxidative Stress Markers
TEST_code
|
CME Activity Information |
|
Release Date: |
October 03, 2007 |
|
Most Recent Review: |
October 03, 2007* |
|
Most Recent Update: |
October 03, 2007 |
|
Date Credit Expires: |
October 03, 2009 |
|
Time to Complete: |
1 hour |
|
Medium: |
Internet Online |
|
*Click here
to learn more about our review process. |
Instructions for Participation
- Read the following information before beginning the educational activity
and click the "Take this course" link at the bottom of the page
- Study the educational activity
- Complete the CME quiz and evaluation
- After successful completion of the CME quiz and evaluation, you will receive
the credit or participation certificate
*The CME quiz and evaluation must be completed by October 3, 2009, in order
to receive the credit or participation certificate.
Target Audience
Physicians who wish to advance their current knowledge of clinical cancer medicine
regarding prevention and are involved in providing patient care in a cancer care
environment.
Learning Objectives
After completing this course, the reader should be able to:
- Interpret modern techniques to detect early instrumental and biochemical
signs of epirubicin-induced myocardial dysfunction.
- Evaluate the correlation between instrumental signs and biochemical/biological
variables with the aim of more exhaustively defining the clinical effects
of drugs.
- Discuss the effectiveness and safety of an important antineoplastic drug
such as epirubicin.
Accreditation and Credit Designation
This activity has been planned and implemented in accordance
with the Essential Areas and policies of the Accreditation Council for Continuing
Medical Education (ACCME) through the joint sponsorship of the School of Medicine
of The University of North Carolina at Chapel Hill and The Oncologist.
The School of Medicine of The University of North Carolina at Chapel Hill is accredited
by the ACCME to provide continuing medical education for physicians.
The School
of Medicine of The University of North Carolina at Chapel Hill designates this
educational activity for a maximum of 1.00 AMA PRA Category 1 Credit™.
Physicians should only claim credit commensurate with the extent of their participation
in the activity.
Commercial Support
Non-governmental supporters of this activity: Abraxis BioScience,
AstraZeneca, Bristol-Myers Squibb Oncology, Merck, Pfizer, and sanofi-aventis
Disclosure Policy
In compliance with the Standards of the ACCME, it is the policy of the School
of Medicine of The University of North Carolina at Chapel Hill to ensure balance,
independence, objectivity, and scientific rigor in all of its educational activities
and to include information free of commercial bias and based on the best evidence
available. All individuals in a position to influence the content of this activity
have disclosed relevant financial interests or relationships of their own, their
spouse/partner, or their worksite, with manufacturers or providers of commercial
products, services, technology, or programs; and disclosed relationships with
current non-governmental supporters of the activity.
All information is submitted and reviewed and found to be scientifically rigorous,
based on the best available evidence, fair and balanced, and free of commercial
bias. All the recommendations involving clinical medicine in this CME activity
are based on evidence that is accepted within the profession of medicine as
adequate justification for their indications and contraindications in the care
of patients. All scientific research referred to, reported or used in CME in
support or justification of a patient care recommendation conforms to the generally
accepted standards of experimental design, data collection and analysis.
Any potential conflicts of interests are resolved via The Oncologist's
anonymous peer review process
All manuscripts are reviewed by the Editorial Board with ad hoc assistance from
two or more external experts in the field. All final publication decisions are
made by the Editorial Board. The acceptance of a manuscript is based on its
originality and importance to the field as assessed by the Editors.
Content Review
The content of this manuscript has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias.
Author Disclosure(s)
Giuseppe Mercuro, M.D.
Credentials: Department of Cardiovascular and Neurological
Sciences, University of Cagliari, Cagliari, Italy.
Disclosures: The author has indicated no relevant commercial
relationships.
Christian Cadeddu, M.D.
Credentials: Department of Cardiovascular and Neurological
Sciences, University of Cagliari, Cagliari, Italy.
Disclosures: The author has indicated no relevant commercial
relationships.
Alessandra Piras, M.D.
Credentials: Department of Cardiovascular and Neurological
Sciences, University of Cagliari, Cagliari, Italy.
Disclosures: The author has indicated no relevant commercial
relationships.
Mariele Desś, M.D.
Credentials: Medical Oncology, University of Cagliari,
Cagliari, Italy.
Disclosures: The author has indicated no relevant commercial
relationships.
Clelia Madeddu, M.D.
Credentials: Medical Oncology, University of Cagliari,
Cagliari, Italy.
Disclosures: The author has indicated no relevant commercial
relationships.
Martino Deidda, M.D.
Credentials: Department of Cardiovascular and Neurological
Sciences, University of Cagliari, Cagliari, Italy.
Disclosures: The author has indicated no relevant commercial
relationships.
Roberto Serpe, M.D.
Credentials: Medical Oncology, University of Cagliari,
Cagliari, Italy.
Disclosures: The author has indicated no relevant commercial
relationships.
Elena Massa, M.D.
Credentials: Medical Oncology, University of Cagliari,
Cagliari, Italy.
Disclosures: The author has indicated no relevant commercial
relationships.
Giovanni Mantovani, M.D.
Credentials: Medical Oncology, University of Cagliari,
Cagliari, Italy. Telephone: 0039-070-5109-6253; Fax:
0039-070-5109-6253; E-mail: mantovan{at}pacs.unica.it.
Disclosures: The author has indicated no relevant commercial
relationships.
Section Editors Disclosures
Eddie Reed, M.D., and Hans-Joerg Senn, M.D., have disclosed no financial relationships relevant to the content of this article.
CME Activity Director Disclosure
Frank M. Balis, M.D., CME Activity Director, Clinical Director, National Cancer Institute, has disclosed no financial relationships relevant to the content of this article.
Independent Peer Reviewers and Staff Managers Disclosures
No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers or staff managers.
Hardware/Software Requirements
The Oncologist CME Online supports
the following browsers: Current production versions of Opera, Safari, Firefox,
Lynx and Mozilla; Netscape 6.1 and above, and Explorer 6.0 and above. The Macintosh
version of Explorer was discontinued in June 2003, and is not supported.
Other Links
Disclaimer
Privacy statement
Correspondence
The Oncologist CME Online
c/o AlphaMed Press
318 Blackwell Street, Suite 260
Durham, North Carolina 27701
Phone: (919) 680-0011
Fax: (919) 680-4411
Email: angela.davies{at}ucdmc.ucdavis.edu
Copyright © 2009 by AlphaMed Press.